Author: "Anne- Sophie Moreau" / Language: undetermined - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Anne- Sophie Moreau"' showing total 144 results

Start Over Author "Anne- Sophie Moreau" Language undetermined

144 results on '"Anne- Sophie Moreau"'

1. Prise en charge du syndrome de relargage cytokinique et du syndrome d’activation macrophagique après traitement par CAR-T cells : recommandations de la SFGM-TC

Author: Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, Corinne Courbon, Franciane Paul, Muriel Picard, Cécile Pochon, Arthur Sterin, Céline Vicente, Emmanuel Canet, Ibrahim Yakoub-Agha, and Anne-Sophie Moreau
Subjects: Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine
Published: 2023
Full Text: View/download PDF

2. Prise en charge du syndrome de neurotoxicité associée au traitement par cellules CAR-T chez l’adulte et l’enfant : recommandations de la SFGM-TC

Author: Muriel Picard, Arthur Sterin, Jacques-Olivier Bay, Corinne Courbon, Anne- Sophie Moreau, Franciane Paul, Cécile Pochon, Jean-Jacques Tudesq, Céline Vicente, Mathilde Yakoub-Agha, and Ibrahim Yakoub-Agha
Subjects: Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine
Published: 2023
Full Text: View/download PDF

3. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non–small-Cell Lung Cancer Involvement in the ICU

Author: Damien Contou, Frédéric Gonzalez, Anne-Sophie Moreau, M. Pineton de Chambrun, E. De Montmollin, Romain Persichini, Florent Wallet, Anne Oppenheimer, Aude Gibelin, N. Dufour, Jean-Damien Ricard, Stéphane Gaudry, Julien Mayaux, P. Jaubert, Y. Akrour, Annabelle Stoclin, Alexandre Lautrette, Y. Tandjaoui-Lambiotte, B. Duchemann, F. El Kouari, and Khalil Chaïbi
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, MEDLINE, Adenocarcinoma of Lung, Critical Care and Intensive Care Medicine, law.invention, Erlotinib Hydrochloride, Crizotinib, law, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Acute respiratory failure, Lung cancer, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Retrospective Studies, Acrylamides, Aniline Compounds, Noninvasive Ventilation, business.industry, Oxygen Inhalation Therapy, Gefitinib, Middle Aged, medicine.disease, Respiration, Artificial, Intensive care unit, ErbB Receptors, Survival Rate, Intensive Care Units, Female, Non small cell, Respiratory Insufficiency, Cardiology and Cardiovascular Medicine, business, Tyrosine kinase
Published: 2022
Full Text: View/download PDF

4. Critically ill patients with severe infections related to Geotrichum species: A French retrospective multicentre study

Author: Nadia Aissaoui, Benoit Champigneulle, Muriel Picard, Michael Darmon, Andrine Valade, Anne Sophie Moreau, Julien Mayaux, Laure Calvet, Etienne de Montmollin, Fabrice Bruneel, Frédéric Pène, Martin Murgier, Florence Boissier, Laurent Argaud, Elie Azoulay, Naïke Bigé, Djamel Mokart, CarMeN, laboratoire, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier de Versailles André Mignot (CHV), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Sorbonne Paris Cité (USPC), Université Paris Descartes - Paris 5 (UPD5), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], CHU Pitié-Salpêtrière [AP-HP], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Lille, and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)
Subjects: Adult, Antifungal, medicine.medical_specialty, multiple organ failure, medicine.drug_class, health care facilities, manpower, and services, [SDV]Life Sciences [q-bio], Critical Illness, Dermatology, Internal medicine, Intensive care, medicine, Humans, Geotrichum species, Hospital Mortality, intensive care, Retrospective Studies, invasive fungal infections, Adult patients, business.industry, Critically ill, Geotrichosis, General Medicine, Middle Aged, Geotrichum, Icu admission, [SDV] Life Sciences [q-bio], Intensive Care Units, Infectious Diseases, Respiratory failure, outcome, SOFA score, France, business
Abstract: International audience; OBJECTIVES: Geotrichum spp can be responsible for severe infections in immunocompromised patients. We aim to describe Geotrichum-related infections in the ICU and to assess risk factors of mortality. METHODS: Retrospective multicentre study, conducted in 14 French ICUs between 2002 and 2018, including critically ill adult patients with proven or probable infection related to Geotrichum species. Data were obtained from the medical charts. RESULTS: Thirty-six patients, median age 60 years IQR [53; 66] were included. Most of the patients had haematological malignancies (78%). The reason for ICU admission was shock in half of the patients (n = 19, 53%) and respiratory failure in thirteen patients (36%). Median SOFA score was 8.5 IQR [7; 15]. Time between ICU admission and fungal diagnosis was 2.5 days [-1; 4]. Infection was disseminated in 27 (75%) patients with positive blood cultures in 25 patients (69%). Thirty patients (83%) received curative antifungal treatment in the ICU, in a median time of 1 day [0;1] after ICU admission. Twenty-four patients (67%) died in the ICU and hospital mortality rate was 69%. The number and extent of organ failures, as represented by SOFA score, were associated with mortality. CONCLUSIONS: This study demonstrates poor outcome in critically ill patients with Geotrichum-related infections, which encourages a high level of suspicion.
Published: 2021
Full Text: View/download PDF

5. Complications des cellules CAR-T autres que les infections, CRS et ICANS : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author: Ibrahim Yakoub-Agha, Cécile Pochon, Céline Vicente, Mathilde Yakoub-Agha, Anne-Sophie Moreau, Arthur Sterin, Corinne Courbon, Muriel Picard, Jean-Jacques Tudesq, Jacques-Olivier Bay, and Franciane Paul
Subjects: Cancer Research, medicine.medical_specialty, Bone marrow transplantation, business.industry, Hematology, General Medicine, medicine.disease, Tumor lysis syndrome, Cell therapy, Therapeutic approach, Graft-versus-host disease, Oncology, Internal medicine, Epidemiology, medicine, Radiology, Nuclear Medicine and imaging, Car t cells, business, Multiple myeloma
Abstract: CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell therapy, that were first described as exceptional, have now been reported in series of patients, since its first clinical use in 2011. Among them, cardiac complications, delayed cytopenias, acute and chronic Graft versus Host Disease, and tumoral lysis syndrome are recognized as specific potent complications following CAR T-cells infusion. During the twelfth edition of practice harmonization workshops of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), a working group focused its work on the management of these complications with focuses the epidemiology, the physiopathology and the risk factors of these 4 side effects. Our recommendations apply to commercial CAR-T cells, in order to guide strategies for the management of complications associated with this new therapeutic approach.
Published: 2021
Full Text: View/download PDF

6. Prise en charge prophylactique, thérapeutique des complications infectieuses et vaccination des patients traités par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author: Franciane Paul, Céline Vicente, Corinne Courbon, Anne-Sophie Moreau, Muriel Picard, Cécile Pochon, Arthur Sterin, Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, and Ibrahim Yakoub-Agha
Subjects: Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine
Published: 2021
Full Text: View/download PDF

7. Erratum to 'When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study' [Bull. Cancer 109 (2022) 916–24]

Author: Anne-Pascale Meert, Anne-Claire Toffart, Muriel Picard, Paul Jaubert, Aude Gibelin, Philippe Bauer, Djamel Mokart, Andry Van De Louw, Stefan Hatzl, Gabriel Moreno-Gonzales, Gaelle Rousseau-Bussac, Fabrice Bruneel, Luca Montini, Anne-Sophie Moreau, Dorothée Carpentier, Amelie Seguin, Pleun Hemelaar, Elie Azoulay, and Virginie Lemiale
Subjects: Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine
Published: 2023
Full Text: View/download PDF

8. Sepsis-associated coagulopathy in onco-hematology patients presenting with thrombocytopenia: a multicentric observational study

Author: Virginie, Lemiale, Asma, Mabrouki, Loïc, Miry, Djamel, Mokart, Frédéric, Pène, Achille, Kouatchet, Julien, Mayaux, Fabrice, Bruneel, Pierre, Perez, Anne-Pascale, Meert, Anne-Sophie, Moreau, Dominique, Benoit, Michael, Darmon, Lara, Zafrani, and Raphaël, Clere-Jehl
Abstract: Coagulation disorders increase mortality rate during septic shock, but the impact of concomitant hematological malignancies remains unknown. The study assessed coagulation disorders in onco-hematological patients with thrombocytopenia (100 G/L) admitted to ICU for septic shock. Among 146 included patients, 50 patients had lymphoma and 49 patients had acute leukemia. ICU mortality rate was 43.8% (
Published: 2022

9. Vascular skin manifestations in patients with severe COVID-19 in intensive care units: a monocentric prospective study

Author: Alain Duhamel, F. Dezoteux, Baptiste Mille, Daniel Mathieu, Anne-Sophie Moreau, Charlotte Fievet, Julien Poissy, Elodie Drumez, Delphine Staumont-Sallé, and S. Buche
Subjects: medicine.medical_specialty, Clinical Report, SARS-CoV-2, business.industry, coronavirus, COVID-19, Dermatology, Fibrinogen, intensive care unit, Intensive care unit, Rash, Pathophysiology, law.invention, vascular skin manifestations, law, Intensive care, Internal medicine, Ambulatory, Medicine, Observational study, medicine.symptom, business, Prospective cohort study, chilblain, medicine.drug
Abstract: Background Various skin manifestations have been reported during the coronavirus disease 2019 (COVID-19) pandemic. Among these are acral vascular skin lesions in non-severe patients, but few studies have focused specifically on patients with severe COVID-19 admitted to the intensive care unit (ICU). Objectives We aimed to assess the frequency of acral vascular skin manifestations (AVSM) in patients admitted to the ICU based on systematic dermatological examination. Materials & Methods We conducted a clinical, observational and prospective study in the ICU of Lille University Hospital (France). All adult patients with RT-PCR-confirmed severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection were included on May 5th and 6th, 2020. Results A total of 39 patients with severe COVID-19 were examined (34 males and five females; median age: 61 [55–59]). We observed AVSM in 11/39 patients (28%) including five with acral necrotic lesions, three with haemorrhagic blisters, one with acral live-doid rash, and one with erosive distal lesions. Chilblain or chilblain-like lesions were not seen, unlike ambulatory or non-severe patients described in the literature. There was no difference regarding the median length of stay in the ICU, initial symptoms of COVID-19 or baseline characteristics, except for a lower BMI in patients with AVSM. All patients had biological coagulation abnormalities (e.g. higher levels of fibrinogen or D-dimers), but there was no difference between patients with and without AVSM. Conclusion AVSM are infrequent and heterogenous and seem to be non-specific to patients with severe SARS-CoV-2, and possibly unrelated to COVID-19. The pathophysiology of AVSM described during the COVID-19 pandemic is not fully elucidated.
Published: 2021
Full Text: View/download PDF

10. Non–C. difficileClostridioides Bacteremia in Intensive Care Patients, France

Author: Guillaume Morel, Romain Sonneville, Damien Contou, David Rousset, Djamel Mokart, Amélie Seguin, Bruno Mégarbane, Lucie Biard, Moustafa Abdel Nabey, Guillaume Dumas, Guillaume Voiriot, Anne-Sophie Moreau, Laura Platon, Yacine Tandjaoui, Elie Azoulay, Muriel Picard, Achille Kouatchet, Frédéric Pène, Guillaume Mulier, Lara Zafrani, Etienne Ghrenassia, Isabelle Oddou, Hôpital de Hautepierre [Strasbourg], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Lapeyronie [Montpellier] (CHU), Hôpital Cochin [AP-HP], Hôpital Roger Salengro [Lille], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Victor Dupouy, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], CHU Tenon [AP-HP], CHU Strasbourg, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and Mégarbane, Bruno
Subjects: Microbiology (medical), medicine.medical_specialty, Critical Care, Epidemiology, Infectious and parasitic diseases, RC109-216, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Clostridium, Clostridioides, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Intensive care, medicine, Humans, Non–C. difficile Clostridioides Bacteremia in Intensive Care Patients, France, bacteremia, bacteria, intensive care, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, biology, business.industry, Research, medicine.disease, C difficile, biology.organism_classification, Hemolysis, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.TOX] Life Sciences [q-bio]/Toxicology, Infectious Diseases, [SDV.TOX]Life Sciences [q-bio]/Toxicology, Bacteremia, ICU, Clostridium Infections, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, France, hemolysis, business
Abstract: Article Summary: This multicenter study focusing on critically ill patients showed a strong relationship between hemolysis and mortality., Usually responsible for soft tissue infections, Clostridioides species can also cause bacteremia, life-threatening infections often requiring intensive care unit (ICU) admission. We conducted a multicenter retrospective study to investigate Clostridioides bacteremia in ICUs to describe the clinical and biologic characteristics and outcomes in critically ill patients. We identified 135 patients with Clostridioides bacteremia, which occurred almost exclusively (96%) in patients with underlying conditions. Septic shock and digestive symptoms were the hallmarks of Clostridioides bacteremia in the ICU. We identified 16 different species of Clostridioides, among which C. perfringens accounted for 31% of cases. Despite the high sensitivity of Clostridioides to common antimicrobial drugs, mortality rates were high: 52% for ICU patients and 71% overall at 3 months. In multivariate analysis, the most important factor associated with increased risk for death was the presence of hemolysis. Clostridioides bacteremia often leads to multiple organ failures, which have high mortality rates.
Published: 2021
Full Text: View/download PDF

11. Maladie de Rosai-Dorfman-Destombes (RDD) multifocale réfractaire associée à un syndrome myélodysplasique. Efficacité du traitement hématologique

Author: Caroline Bodet-Milin, Anne-Sophie Moreau, M. Hamidou, Antoine Néel, Agathe Masseau, M. Eustache, R. Deshayes, and Pierre Peterlin
Subjects: Gynecology, medicine.medical_specialty, business.industry, Gastroenterology, Internal Medicine, Medicine, business
Abstract: Resume Introduction Nous rapportons une observation originale de maladie de Destombes-Rosai-Dorfman multifocale et refractaire, associee a un syndrome myelodysplasique. Le traitement de la myelodysplasie a permis une tres bonne reponse prolongee des 2 pathologies. Observation Un patient de 35 ans etait explore pour une exophtalmie bilaterale, rapportee histologiquement a une maladie de maladie de Destombes-Rosai-Dorfman. Le bilan d’extension retrouvait une atteinte sinusienne, renale et ganglionnaire. Il etait traite successivement, sans succes, par corticoides, colchicine, methotrexate, infliximab, cladribine et tociluzimab. L’apparition secondaire d’une myelodysplasie (AREB score IPSS intermediaire-2) faisait proposer un traitement d’induction par aracytine et idarubicine, avec entretien par azacytidine pendant 2 ans. Avec un recul de 5 ans, le patient est en remission du syndrome myelodysplasique et de la maladie de Destombes-Rosai-Dorfman. Conclusion Notre observation discute l’interet du traitement du syndrome myelodysplasique, dans la prise en charge des manifestations extra-hematologiques associees.
Published: 2021
Full Text: View/download PDF

12. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Author: Marie-Therese Rubio, Roberta Di Blasi, Gilles Salles, Miguel A Perales, Kada Klouche, Muriel Picard, Pierre Sesques, Eric Mariotte, Michael Darmon, Boris Böll, Philippe R. Bauer, Sanjay Chawla, Kevin Rakszawski, Nahema Issa, Anne Huynh, Guillaume Cartron, Florence Rabian, Peter Borchmann, Michael Joannidis, Sabine Furst, Sophie de Guibert, Lara Zafrani, Patrice Ceballos, Nicolas Boissel, David Beauvais, Catherine Thieblemont, François-Xavier Gros, Alberto Mussetti, Gabriel Moreno-González, Adel Maamar, Florent Wallet, Faezeh Legrand, Julien Leroy, Quentin Quelven, Djamel Mokart, Valentin Ortiz, Christian Recher, Jakob Rudzki, Laura Platon, Pleun Hemelaar, Benoit Tessoulin, Reuben Benjamin, Sandrine Valade, Pedro Castro, Gennadii Galstian, Amélie Seguin, Peter Schellongowski, Anna Sureda, Alice Gallo De Moraes, Philipp Wohlfarth, Bruno Levy, Andry Van de Louw, Jorge Garcia Borrega, Julio Delgado, Ibrahim Yakoub-Agha, Nathalie Fégueux, Laveena Munshi, Yi Lin, Emmanuel Bachy, Stéphanie Harel, Sara Fernández, Bertrand Arnulf, Thomas Gastinne, Elie Azoulay, Didier Blaise, Amandine Le Bourgeois, Louis Voigt, Cécile Borel, Anne-Sophie Moreau, Christian Chabannon, Ulrich Jäger, Virginie Lemiale, Olga Gavrilina, Victoria Metaxa, Thomas Staudingert, Edouard Forcade, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Barcelona, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), King's College Hospital (KCH), Mayo Clinic [Rochester], Memorial Sloane Kettering Cancer Center [New York], Weill Medical College of Cornell University [New York], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Roger Salengro [Lille], Penn State Health Milton S. Hershey Medical Center, Pennsylvania Commonwealth System of Higher Education (PCSHE)-Penn State System, Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Universitätsklinikum Köln (Uniklinik Köln), Hôpital Saint-André, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Radboud University Medical Center [Nijmegen], Universitat de Barcelona (UB), University of Toronto, Medizinische Universität Wien = Medical University of Vienna, Leopold Franzens Universität Innsbruck - University of Innsbruck, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Soins Intensifs [CHRU Nancy], Radboud University Medical Centre [Nijmegen, The Netherlands], University of Innsbruck, and National Research Center for Hematology [Moscow, Russia]
Subjects: Male, MESH: Neurotoxicity Syndromes, MESH: Registries, [SDV]Life Sciences [q-bio], MESH: Multiple Myeloma, Immunotherapy, Adoptive, Severity of Illness Index, law.invention, MESH: Proportional Hazards Models, Medicina intensiva, Clinical trials, 0302 clinical medicine, law, Clinical endpoint, Medicine, Infection control, Registries, MESH: Treatment Outcome, MESH: Middle Aged, Medical record, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intensive care unit, 3. Good health, Survival Rate, Cytokine release syndrome, Intensive Care Units, Treatment Outcome, 030220 oncology & carcinogenesis, MESH: Immunotherapy, Adoptive, Female, Neurotoxicity Syndromes, Lymphoma, Large B-Cell, Diffuse, Cytokine Release Syndrome, Multiple Myeloma, Care of the sick, Cohort study, Adult, medicine.medical_specialty, Critical Care, MESH: Survival Rate, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], MESH: Cytokine Realease Syndrome, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, MESH: Critical Care, Internal medicine, Intensive care, MESH: Severity of Illness Index, Humans, Cura dels malalts, Critical care medicine, Proportional Hazards Models, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH: Humans, business.industry, MESH: Lymphomz, Large B-Cell, Diffuse, MESH: Adult, MESH: Intensive care Units, medicine.disease, MESH: Male, business, MESH: Female, Assaigs clínics, 030215 immunology, Follow-Up Studies
Abstract: Summary Background Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care. Methods This international, multicentre, observational cohort study was done in 21 intensive care units in France, Spain, the USA, the UK, Russia, Canada, Germany, and Austria. Eligible patients were aged 18 years or older; had received CAR T-cell therapy in the past 30 days; and had been admitted to intensive care for any reason. Investigators retrospectively included patients admitted between Feb 1, 2018, and Feb 1, 2019, and prospectively included patients admitted between March 1, 2019, and Feb 1, 2020. Demographic, clinical, laboratory, treatment, and outcome data were extracted from medical records. The primary endpoint was 90-day mortality. Factors associated with mortality were identified using a Cox proportional hazard model. Findings 942 patients received CAR T-cell therapy, of whom 258 (27%) required admission to intensive care and 241 (26%) were included in the analysis. Admission to intensive care was needed within median 4·5 days (IQR 2·0–7·0) of CAR T-cell infusion. 90-day mortality was 22·4% (95% CI 17·1–27·7; 54 deaths). At initial evaluation on admission, isolated cytokine release syndrome was identified in 101 patients (42%), cytokine release syndrome and ICANS in 93 (39%), and isolated ICANS in seven (3%) patients. Grade 3–4 cytokine release syndrome within 1 day of admission to intensive care was found in 50 (25%) of 200 patients and grade 3–4 ICANS in 38 (35%) of 108 patients. Bacterial infection developed in 30 (12%) patients. Life-saving treatments were used in 75 (31%) patients within 24 h of admission to intensive care, primarily vasoactive drugs in 65 (27%) patients. Factors independently associated with 90-day mortality by multivariable analysis were frailty (hazard ratio 2·51 [95% CI 1·37–4·57]), bacterial infection (2·12 [1·11–4·08]), and lifesaving therapy within 24 h of admission (1·80 [1·05–3·10]). Interpretation Critical care management is an integral part of CAR T-cell therapy and should be standardised. Studies to improve infection prevention and treatment in these high-risk patients are warranted. Funding Groupe de Recherche Respiratoire en Reanimation Onco-Hematologique.
Published: 2021
Full Text: View/download PDF

13. Neurologic outcome of VZV encephalitis one year after ICU admission: a multicenter cohort study

Author: Adrien Mirouse, Romain Sonneville, Keyvan Razazi, Sybille Merceron, Laurent Argaud, Naïke Bigé, Stanislas Faguer, Pierre Perez, Guillaume Géri, Claude Guérin, Anne-Sophie Moreau, Laurent Papazian, René Robert, François Barbier, Frédérique Ganster, Julien Mayaux, Elie Azoulay, Emmanuel Canet, CarMeN, laboratoire, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], CHU Henri Mondor, Centre Hospitalier de Versailles André Mignot (CHV), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré [AP-HP], Université Paris-Saclay, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Nord [CHU - APHM], CHU Lille, Assistance Publique - Hôpitaux de Marseille (APHM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital La Source [Orléans] (HLSO), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Université Paris Cité (UPCité), Centre hospitalier universitaire de Nantes (CHU Nantes), and CHU Toulouse [Toulouse]
Subjects: [SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], Acute brain injury, Encephalitis, Varicella-zoster virus, Intensive care unit, Long-term prognosis, Critical Care and Intensive Care Medicine, Virus
Abstract: Background Varicella-zoster virus (VZV) is one of the main viruses responsible of acute encephalitis. However, data on the prognosis and neurologic outcome of critically ill patients with VZV encephalitis are limited. We aimed to describe the clinical features of VZV encephalitis in the ICU and to identify factors associated with a favorable neurologic outcome. We performed a multicenter cohort study of patients with VZV encephalitis admitted in 18 ICUs in France between 2000 and 2017. Factors associated with a favorable neurologic outcome, defined by a modified Rankin Score (mRS) of 0–2 1 year after ICU admission, were identified by multivariable regression analysis. Results Fifty-five patients (29 (53%) men, median age 53 (interquartile range 36–66)) were included, of whom 43 (78%) were immunocompromised. ICU admission occurred 1 (0–3) day after the onset of neurological symptoms. Median Glasgow Coma Score at ICU admission was 12 (7–14). Cerebrospinal fluid examination displayed a median leukocyte count of 68 (13–129)/mm3, and a median protein level of 1.37 (0.77–3.67) g/L. CT scan and MRI revealed brain lesions in 30% and 66% of the cases, respectively. Invasive mechanical ventilation was implemented in 46 (84%) patients for a median duration of 13 (3–30) days. Fourteen (25%) patients died in the ICU. One year after ICU admission, 20 (36%) patients had a favorable neurologic outcome (mRS 0–2), 12 (22%) had significant disability (mRS 3–5), and 18 (33%) were deceased (lost to follow-up n = 5, 9%). On multivariable analysis, age (OR 0.92 per year, (0.88–0.97), p = 0.01), and invasive mechanical ventilation (OR 0.09 CI 95% (0.01–0.84), p = 0.03) reduced the likelihood of favorable neurologic outcome. Conclusion One in every three critically ill patients with VZV encephalitis had a favorable neurologic outcome 1 year after ICU admission. Older age and invasive mechanical ventilation were associated with a higher risk of disability and death.
Published: 2022
Full Text: View/download PDF

14. Prise en charge pratique d’une encéphalopathie liée au traitement par cellules CAR-T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author: Cécile Borel, David Beauvais, Imran Ahmad, Jérôme Naudin, Anne-Sophie Moreau, Emmanuelle Nicolas-Virelizier, Ibrahim Yakoub-Agha, Lara Platon, Jérôme Cornillon, Marie Ouachée-Chardin, André Baruchel, Asmaa Quessar, Nawal Hadhoum, Stavroula Masouridi-Levrat, and Gabrielle Roth-Guepin
Subjects: 0301 basic medicine, Gynecology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Radiology, Nuclear Medicine and imaging, Car t cells, business
Abstract: Resume L’encephalopathie liee a l’utilisation des lymphocytes dotes de recepteur a l’antigene chimerique (CAR-T) (CAR-T cell-related encephalopathy syndrome, CRES) traduit la neurotoxicite potentielle de cette approche therapeutique et doit etre envisagee devant la survenue de tout symptome neurologique apres l’infusion des cellules CAR-T. Il s’agit du second effet indesirable le plus frequent sous cette therapie et son incidence varie entre 12 et 55 % selon les etudes. Le delai median de survenue des premiers symptomes neurologiques est de quatre jours suivant l’infusion de cellules CAR-T. La duree des symptomes du CRES est comprise generalement entre deux et quatre jours mais des CRES tardifs peuvent survenir. La surveillance fait appel notamment au suivi clinique, a l’imagerie par resonance magnetique et a l’electroencephalographie. La prise en charge, en dehors des mesures symptomatiques, consiste, en premier lieu, en une corticotherapie, les therapies ciblant IL-6 etant plutot reservees aux formes severes. Le but de cet atelier est d’apporter une aide pratique a la prise en charge de cette complication.
Published: 2020
Full Text: View/download PDF

15. Neutropenic Enterocolitis in Critically Ill Patients

Author: Eric Mariotte, Frédéric Pène, Anne Wanquet, Djamel Mokart, Romain Pirracchio, Emmanuel Canet, Virginie Lemiale, Anne-Sophie Moreau, Elie Azoulay, Lara Zafrani, Sybille Merceron, Etienne Lengliné, Baptiste Duceau, and Muriel Picard
Subjects: Adult, Male, medicine.medical_specialty, Antifungal Agents, genetic structures, Critical Illness, medicine.medical_treatment, Population, Disease, Critical Care and Intensive Care Medicine, Severity of Illness Index, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Severity of illness, medicine, Humans, education, Intensive care medicine, Retrospective Studies, Enterocolitis, Chemotherapy, education.field_of_study, business.industry, Neutropenic enterocolitis, Enterocolitis, Neutropenic, 030208 emergency & critical care medicine, Retrospective cohort study, Middle Aged, medicine.disease, Intensive Care Units, Mycoses, 030228 respiratory system, Female, France, medicine.symptom, business, Cohort study
Abstract: Neutropenic enterocolitis occurs in about 5.3% of patients hospitalized for hematologic malignancies receiving chemotherapy. Data from critically ill patients with neutropenic enterocolitis are scarce. Our objectives were to describe the population of patients with neutropenic enterocolitis admitted to an ICU and to investigate the risk factors of invasive fungal disease.A multicentric retrospective cohort study between January 2010 and August 2017.Six French ICUs members of the Groupe de Recherche Respiratoire en Onco-Hématologie research network.Adult neutropenic patients hospitalized in the ICU with a diagnosis of enteritis and/or colitis. Patients with differential diagnosis (Clostridium difficile colitis, viral colitis, inflammatory enterocolitis, mesenteric ischemia, radiation-induced gastrointestinal toxicity, and Graft vs Host Disease) were excluded.None.We included 134 patients (median Sequential Organ Failure Assessment 10 [8-12]), with 38.8% hospital mortality and 32.1% ICU mortality rates. The main underlying malignancies were acute leukemia (n = 65, 48.5%), lymphoma (n = 49, 36.6%), solid tumor (n = 14, 10.4%), and myeloma (n = 4, 3.0%). Patients were neutropenic during a median of 14 days (9-22 d). Infection was documented in 81 patients (60.4%), including an isolated bacterial infection in 64 patients (47.8%), an isolated fungal infection in nine patients (6.7%), and a coinfection with both pathogens in eight patients (5.0%). Radiologically assessed enteritis (odds ratio, 2.60; 95% CI, 1.32-7.56; p = 0.015) and HIV infection (odds ratio, 2.03; 95% CI, 1.21-3.31; p = 0.016) were independently associated with invasive fungal disease.The rate of invasive fungal disease reaches 20% in patients with neutropenic enterocolitis when enteritis is considered. To avoid treatment delay, antifungal therapy might be systematically discussed in ICU patients admitted for neutropenic enterocolitis with radiologically assessed enteritis.
Published: 2019
Full Text: View/download PDF

16. Sinusoidal Obstruction Syndrome in Critically Ill Patients in the Era of Defibrotide: A Retrospective Multicenter Study

Author: Pierre-Edouard Debureaux, Michael Darmon, Elie Azoulay, Emmanuel Canet, Julien Mayaux, Claire Lacan, Pierre Perez, Sandrine Valade, Achille Kouatchet, Naïke Bigé, Muriel Picard, Martin Murgier, Florent Wallet, Anne Sophie Moreau, Djamel Mokart, Frédéric Pène, and Guillaume Morel
Subjects: Adult, medicine.medical_specialty, medicine.medical_treatment, Critical Illness, Hepatic Veno-Occlusive Disease, Defibrotide, law.invention, Polydeoxyribonucleotides, law, medicine, Immunology and Allergy, Humans, Renal replacement therapy, Aged, Retrospective Studies, Mechanical ventilation, Transplantation, business.industry, Hazard ratio, Acute kidney injury, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Cell Biology, Hematology, medicine.disease, Intensive care unit, Respiratory failure, Emergency medicine, Molecular Medicine, business, medicine.drug
Abstract: Sinusoidal obstruction syndrome (SOS) is a life-threatening liver complication of high- dose chemotherapy. Defibrotide is the only available therapeutic option approved for SOS. The prognosis of SOS in patients requiring intensive care unit (ICU) admission remains unknown. The primary objective of this study was to assess the outcome of SOS patients in ICU. This retrospective study was conducted between 2007 and 2019 in 13 French ICUs. Seventy-one critically ill adult patients with SOS defined according to European Society for Blood and Marrow Transplantation criteria and treated with defibrotide were included. The main reasons for ICU admission were respiratory failure and acute kidney injury. Mechanical ventilation, vasopressors, and renal replacement therapy were required in 59%, 52%, and 49% of patients, respectively. Twenty-three percent of patients experienced a bleeding event during defibrotide treatment. Hospital mortality was 54%, mainly related to multiorgan failure. Older age (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.00 to 1.04), mechanical ventilation (HR, 1.99; 95% CI, 1.00 to 3.99), renal replacement therapy (HR, 2.55; 95% CI, 1.32 to 4.91) were independent predictors of hospital mortality. Defibrotide prophylaxis (HR, 0.35; 95% CI, 0.13 to 0.92) was associated with better outcomes. Critically ill patients with SOS have a high mortality rate in the ICU, especially if organ support is required. Additional studies assessing the impact of defibrotide prophylaxis are warranted.
Published: 2020

17. Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l’adulte et l’enfant : recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author: Ibrahim Yakoub-Agha, Lara Platon, Jérôme Cornillon, Gabrielle Roth-Guepin, Nawal Hadhoum, Jérôme Naudin, Cécile Borel, Marie Ouachée-Chardin, Imran Ahmad, André Baruchel, Asmaa Quessar, Anne-Sophie Moreau, Stavroula Masouridi-Levrat, Emmanuelle Nicolas-Virelizier, and Davis Beauvais
Subjects: 0301 basic medicine, myalgia, Cancer Research, business.industry, T cell, Encephalopathy, Hematology, General Medicine, medicine.disease, Chimeric antigen receptor, Cell therapy, 03 medical and health sciences, Cytokine release syndrome, Interleukin 10, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Intensive care, Immunology, medicine, Radiology, Nuclear Medicine and imaging, medicine.symptom, business
Abstract: The cytokine release syndrome (CRS) is the most common complication after adoptive immunotherapies such as chimeric antigen receptor T cells (CAR-T). The incidence varies from 30 to 100% depending on the CAR-T construct, cell doses and the underlying disease. Severe cases may involve 10 to 30% of patients. The triggering event is the activation of the CAR-T, after meeting with their target. The T cell activation leads to the release of effector cytokines, such as IFNγ, TNFα and IL2, that are responsible for the activating of monocyte/macrophage system, resulting in the production of pro-inflammatory cytokines, (including IL6, IFN-γ, IL10, MCP1) and associated with a significant elevation of CRP and ferritin. The CRS usually appears between 1 and 14days after the infusion of the cells and can last from 1 to 10days. Rare fatal cases have been reported in the literature. The first symptom is often a fever, sometimes very high, which must alert and reinforce the surveillance. In moderate forms, one can find fatigue, headache, rash, arthralgia and myalgia. T cell-related encephalopathy (CRES) syndrome may occur concomitantly. In case of aggravation, a vasoplegic shock associating capillary leakage and respiratory distress can occur. Close clinical monitoring is essential right from the injection to quickly detect the first symptoms. The treatment of severe forms, in addition to symptomatic management involves monoclonal antibodies targeting the IL6 or IL6 receptor, and sometimes steroids. Close cooperation with intensive care units is essential since 20 to 50% of patients require intensive care unit transfer.
Published: 2019
Full Text: View/download PDF

18. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence

Author: Julien Poissy, Julien Goutay, Morgan Caplan, Erika Parmentier, Thibault Duburcq, Fanny Lassalle, Emmanuelle Jeanpierre, Antoine Rauch, Julien Labreuche, Sophie Susen, Nicolas Cousin, Arthur Durand, Ahmed El Kalioubie, Raphaël Favory, Patrick Girardie, Marion Houard, Emmanuelle Jaillette, Mercé Jourdain, Geoffrey Ledoux, Daniel Mathieu, Anne-Sophie Moreau, Christopher Niles, Saad Nseir, Thierry Onimus, Sébastien Préau, Laurent Robriquet, Anahita Rouzé, Arthur Simonnet, Sophie Six, Aurélia Toussaint, Annabelle Dupont, Anne Bauters, Christophe Zawadzki, Camille Paris, Nathalie Trillot, Bénédicte Wibaut, Audrey Hochart, Catherine Marichez, Vincent Dalibard, Sandrine Vanderziepe, Laureline Bourgeois, Anaïs Gaul, Aurélie Jospin, Nataliia Stepina, Bénédicte Pradines, Antoine Tournoys, Thierry Brousseau, Martine Rémy, and Antoine Hutt
Subjects: Adult, Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, 030204 cardiovascular system & hematology, Gastroenterology, Article, Tertiary Care Centers, 03 medical and health sciences, Betacoronavirus, 0302 clinical medicine, Von Willebrand factor, Fibrinolytic Agents, Risk Factors, Physiology (medical), Internal medicine, D-dimer, Pandemic, medicine, Prevalence, Humans, In patient, 030212 general & internal medicine, Pandemics, Aged, Aged, 80 and over, biology, business.industry, SARS-CoV-2, COVID-19, Length of Stay, Middle Aged, medicine.disease, Prognosis, Thrombosis, Pulmonary embolism, Intensive Care Units, biology.protein, Female, Cardiology and Cardiovascular Medicine, business, Coronavirus Infections, Pulmonary Embolism, Body mass index
Published: 2020

19. A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma

Author: David, Beauvais, Adeline, Cozzani, Anne-Sophie, Blaise, Anne-Sophie, Moreau, Pauline, Varlet, Silvia, Gaggero, Enagnon Kazali, Alidjinou, Quentin, Vannod-Michel, Franck, Morschhauser, Myriam, Labalette, Ibrahim, Yakoub-Agha, and Suman, Mitra
Subjects: Receptors, Chimeric Antigen, Antigens, CD19, Cytokines, Humans, Neurotoxicity Syndromes, Lymphoma, Large B-Cell, Diffuse, General Medicine, Cytokine Release Syndrome, Immunotherapy, Adoptive, Spinal Cord Diseases, General Biochemistry, Genetics and Molecular Biology
Abstract: The event of anti-CD19 chimeric antigen receptor (CAR)-T therapy inducing serious neurotoxicity in patients with diffuse large B-cell lymphoma (DLBCL) is recognized; however, the patterns of symptoms and severity vary greatly from patient to patient. We report an exceptional presentation of acute myelopathy in a refractory DLBCL following successful CAR-T treatment along with grade 3 cytokine release syndrome (CRS) and neurotoxicity. The patient was initiated on high-dose methylprednisolone (MPS) resulting in rapid improvement of neurological symptoms. Yet the myelopathy patient (MP) experienced severe lower limb motor deficit, and a subsequent spinal cord MRI revealed myelopathy with a sensory level at segment T2. Multimodal therapy consisting of MPS, intravenous immunoglobulin and anakinra therapy resulted in complete reversal of myelopathy condition and the patient remained cancer free. The assessment of time trends of serum cytokines at baseline and post CAR-T infusion in MP compared to other 4 DLBCL complete responder patients with varying degree of CRS following CAR-T infusion, suggested pre-existing baseline inflammatory conditions in MP with altered levels of cytokines. These findings, if corroborated by similar case studies, have the potential to generate novel insights into the manifestation of myelopathy following CAR-T therapy and the successful clinical management of such complications.
Published: 2022
Full Text: View/download PDF

20. 1829P In-hospital survival of metastatic patients admitted into medical intensive care units: A French nationwide study about 57,717 cases

Author: D. Benoit, N. Bertrand, Anne-Sophie Moreau, Emmanuel Chazard, A. Escande, S. Nseir, and G. Ficheur
Subjects: medicine.medical_specialty, Oncology, business.industry, Intensive care, Emergency medicine, medicine, Hematology, business
Published: 2021
Full Text: View/download PDF

21. Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l’antigène (CAR T-cells) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author: Marina Deschamps, Yves Chalandon, Anne-Sophie Moreau, Jérôme Larghero, Cristina Castilla Llorente, Christophe Ferrand, Pauline Varlet, Caroline Ballot, Marie-Odile Pétillon, Camille Maheux, Ibrahim Yakoub-Agha, Christian Chabannon, Marie-Thérèse Rubio, Myriam Labalette, Marine Pinturaud, Jordan Gauthier, Unités d'Activité Médicale [Lille] (UAM), Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Laboratoire des Sciences de l'Information et des Systèmes (LSIS), Centre National de la Recherche Scientifique (CNRS)-Arts et Métiers Paristech ENSAM Aix-en-Provence-Université de Toulon (UTLN)-Aix Marseille Université (AMU), Lille Inflammation Research International Center - U 995 (LIRIC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Université Paris Diderot - Paris 7 (UPD7), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Lille (CHU de Lille), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Aix Marseille Université (AMU)-Université de Toulon (UTLN)-Arts et Métiers Paristech ENSAM Aix-en-Provence-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: 0301 basic medicine, Cancer Research, Genetic enhancement, medicine.medical_treatment, Context (language use), Hematopoietic stem cell transplantation, Bioinformatics, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, Antigen, medicine, Radiology, Nuclear Medicine and imaging, ComputingMilieux_MISCELLANEOUS, business.industry, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Hematology, General Medicine, Chimeric antigen receptor, 3. Good health, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Chimeric Antigen Receptor T-Cell Therapy, business
Abstract: CAR T-cells are autologous or allogeneic human lymphocytes that are genetically engineered to express a chimeric antigen receptor targeting an antigen expressed on tumor cells such as CD19. CAR T-cells represent a new class of medicinal products, and belong to the broad category of Advanced Therapy Medicinal Products (ATMPs), as defined by EC Regulation 2007-1394. Specifically, they are categorized as gene therapy medicinal products. Although CAR T-cells are cellular therapies, the organization for manufacturing and delivery is far different from the one used to deliver hematopoietic cell grafts, for different reasons including their classification as medicinal products. Currently available clinical observations were mostly produced in the context of trials conducted either in the USA or in China. They demonstrate remarkable efficacy for patients presenting advanced or poor-prognosis hematological malignancies, however with severe side effects in a significant proportion of patients. Toxicities can and must be anticipated and dealt with in the context of a full coordination between the clinical cell therapy ward in charge of the patient, and the neighboring intensive care unit. The present workshop aimed at identifying prerequisites to be met in order for French hospitals to get efficiently organized and fulfill sponsors' expectations before initiation of clinical trials designed to investigate CAR T-cells.
Published: 2017
Full Text: View/download PDF

22. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

Author: Philippe Moreau, Pierre Gallas, Pierre Peterlin, Céline Bossard, Cyrille Touzeau, Anne-Sophie Moreau, Thierry Guillaume, A. Lok, Patrice Chevallier, Benoit Tessoulin, N. Blin, J. Moynard, V. Dubruille, F. Perrin, E. Delande, Thomas Gastinne, Patrick Thomaré, Steven Le Gouill, Alice Garnier, Jean-Samuel Boudreault, and Béatrice Mahé
Subjects: Adult, medicine.medical_specialty, Neutropenia, Adolescent, Pharmacology, DHAP Regimen, Transplantation, Autologous, Gastroenterology, Dexamethasone, Disease-Free Survival, Carboplatin, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Autologous stem-cell transplantation, Internal medicine, DHAP, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Retrospective Studies, business.industry, Lymphoma, Non-Hodgkin, Remission Induction, Cytarabine, Anemia, Hematology, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Hodgkin Disease, Thrombocytopenia, Regimen, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Rituximab, Cisplatin, business, Stem Cell Transplantation, 030215 immunology, medicine.drug
Abstract: The DHAP regimen (high-dose cytarabine in combination with dexamethasone and cisplatin) with or without rituximab (DHAP+/−R) is one of the most common regimens in daily practice. It is considered the standard treatment for relapse or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL). Cisplatin nephrotoxicity is a major concern, and other platinum compounds are being tried. We performed a monocentric retrospective analysis to evaluate the use of carboplatin, so-called DHAC+/−R regimen. The purpose was to assess the toxicity of the DHAC+/−R regimen in real-life. The Dexamethasone, Cytarabine, Carboplatin (DHAC) regimen consisted of carboplatin AUC = 5 mg/ml/min (targeted area under the curve with Calvert’s formula) on day 1, cytarabine 2 g/m2 twice a day on day 2 and IV dexamethasone 40 mg from days 1 to 4. Rituximab was administrated at 375 mg/m2 on day 1 for CD20+ NHL. The interval between courses was 21 days. During the period considered, 199 patients received DHAC+/−R. For the entire cohort, median follow-up is 24 months (range, 2–82), median OS is not reached (NR), estimated 2-year OS is 75% (95% CI, 69–83) and median progression-free survival (PFS) is 46 months (95% CI, 22-NA). Of 144 patients scheduled for autologous stem cell transplantation (ASCT), 102 (71%, NA = 2) were in response after DHAC+/−R and all except 4 underwent ASCT. Grade ≥ 3 haematological toxicities were mainly thrombocytopenia (n = 101) and anaemia (n = 95). Grade ≥ 3 neutropenia occurred in 10 patients. No grade ≥ 3 renal and one grade 3 neurological toxicity were reported. DHAC+/−R is feasible in daily practice, provides good response rates and jeopardises neither stem cell collection nor ASCT.
Published: 2017
Full Text: View/download PDF

23. Transfert des patients allogreffés de cellules-souches hématopoïétiques en réanimation : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author: Anne-Sophie Moreau, Edgar Jost, Jean-Henri Bourhis, Ibrahim Yakoub-Agha, Mercé Jourdain, Yosr Hichri, Cécile Dumesnil, Nathalie Contentin, Marie-Anne Couturier, Frédéric Pène, Jeremy Delage, Laura Platon, and Virginie Gandemer
Subjects: Cancer Research, medicine.medical_specialty, law.invention, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, law, Intensive care, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Intensive care medicine, Modalities, Hematology, Marrow transplantation, business.industry, General Medicine, Intensive care unit, 3. Good health, Transplantation, Oncology, 030220 oncology & carcinogenesis, Stem cell, business, 030215 immunology
Abstract: Transferring a patient undergoing an allogeneic stem cell transplantation to the intensive care unit (ICU) is always a challenging situation on a medical and psychological point of view for the patient and his relatives as well as for the medical staff. Despite the progress in hematology and intensive care during the last decade, the prognosis of these patients admitted to the ICU remains poor and mortality is around 50 %. The harmonization working party of the SFGM-TC assembled hematologists and intensive care specialist in order to improve conditions and modalities of the transfer of a patient after allogeneic stem cell transplantation to the ICU. We propose a structured medical form comprising all essential information necessary for optimal medical care on ICU.
Published: 2016
Full Text: View/download PDF

24. Purpuric rash and right infectious endocarditis

Author: Camille Thieffry, Alexandre Pierre, Anne-Sophie Moreau, and Thibault Duburcq
Subjects: medicine.medical_specialty, Endocarditis, business.industry, Pain medicine, MEDLINE, Exanthema, Critical Care and Intensive Care Medicine, medicine.disease, Rash, Dermatology, Anesthesiology, medicine, Humans, medicine.symptom, business
Published: 2018

25. REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE

Author: Tony Petrella, W. El Alami Thomas, Danielle Canioni, Hervé Maisonneuve, O. Laghmari, A. Pavageau, P. Gaulard, Y. Le Bris, C. Copie Bergman, Antoine Bonnet, Josette Brière, P. Guerzider, Marie-Christine Béné, O. Casasnovas, Corinne Haioun, Gilles Salles, Thierry Jo Molina, H. Tilly, Anne-Sophie Moreau, Fabrice Jardin, Céline Bossard, Philippe Ruminy, Catherine Thieblemont, and S. Le Gouill
Subjects: Cancer Research, Oncology, Chemistry, Cell of origin, Double negative, medicine, Hematology, General Medicine, medicine.disease, Molecular biology, Diffuse large B-cell lymphoma
Published: 2019
Full Text: View/download PDF

26. CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR AGRESSIVE MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY

Author: Olivier Hermine, Remy Gressin, Alejandro Martín, Alexandra Traverse-Glehen, Barbara Burroni, M. Baldacini, P. Fogarty, Anne-Sophie Moreau, Danielle Canioni, S. Le Gouill, Luc Mathieu Fornecker, and Marie-Christine Béné
Subjects: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Treatment outcome, Hematology, General Medicine, medicine.disease, Clinical trial, Internal medicine, medicine, Mantle cell lymphoma, business
Published: 2019
Full Text: View/download PDF

27. INCREASED CCND1 FISH SIGNALS ARE ASSOCIATED WITH WORSE PROGNOSIS IN MANTLE CELL LYMPHOMA

Author: Hervé Maisonneuve, Y. Le Bris, Céline Bossard, Benoit Tessoulin, Marie-Christine Béné, Olivier Theisen, S. Le Gouill, Thomas Gastinne, François Subiger, Catherine Godon, David Chiron, Anne-Sophie Moreau, and Mourad Tiab
Subjects: Cancer Research, Cyclin D1, Oncology, Cancer research, medicine, %22">Fish , Mantle cell lymphoma, Hematology, General Medicine, Biology, medicine.disease
Published: 2019
Full Text: View/download PDF

28. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients

Author: Benoit Schlemmer, Frédéric Pène, Elie Azoulay, François Blot, J. H. Bourhis, Agnès Buzyn, Anne-Sophie Moreau, Sylvie Chevret, Etienne Lengliné, and Gérard Socié
Subjects: Adult, Male, medicine.medical_specialty, Critical Care, medicine.medical_treatment, Disease-Free Survival, law.invention, law, Intensive care, Internal medicine, medicine, Humans, Renal replacement therapy, Retrospective Studies, Postoperative Care, Mechanical ventilation, Transplantation, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Allografts, Intensive care unit, Surgery, Icu admission, Advanced life support, Survival Rate, Hematologic Neoplasms, Cohort, Female, Allogeneic hematopoietic stem cell transplant, Unrelated Donors, business, Follow-Up Studies
Abstract: Intensive care unit (ICU) admission is associated with high mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Whether mortality has decreased recently is unknown. The 497 adult allogeneic HSCT recipients admitted to three ICUs between 1997 and 2011 were evaluated retrospectively. Two hundred and nine patients admitted between 1997 and 2003 were compared with the 288 patients admitted from 2004 to 2011. Factors associated with 90-day mortality were identified. The recent cohort was characterized by older age, lower conditioning intensity, and greater use of peripheral blood or unrelated-donor graft. In the recent cohort, ICU was used more often for patients in hematological remission (67% vs 44%; P
Published: 2015
Full Text: View/download PDF

29. The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission

Author: Marc, Pineton de Chambrun, Charles-Edouard, Luyt, François, Beloncle, Marie, Gousseff, Wladimir, Mauhin, Laurent, Argaud, Stanislas, Ledochowski, Anne-Sophie, Moreau, Romain, Sonneville, Bruno, Verdière, Sybille, Merceron, Nathalie, Zappella, Mickael, Landais, Damien, Contou, Alexandre, Demoule, Sylvie, Paulus, Bertrand, Souweine, Bernard, Lecomte, Antoine, Vieillard-Baron, Nicolas, Terzi, Elie, Azoulay, Raymond, Friolet, Marc, Puidupin, Jérôme, Devaquet, Jean-Marc, Mazou, Yannick, Fedun, Jean-Paul, Mira, Jean-Herlé, Raphalen, Alain, Combes, Zahir, Amoura, Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Réanimation Médicale et de Médecine Hyperbare [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP), Centre de recherche en myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Ecole Polytechnique Fédérale de Lausanne (EPFL), Hôpital Bichat - Claude Bernard, Service de soins intensifs, Centre Hospitalier de Versailles André Mignot (CHV), Service de réanimation médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neurophysiologie Respiratoire Expérimentale et Clinique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS)-Université d'Auvergne - Clermont-Ferrand I (UdA), Médecine générale, Service de réanimation medico-chirurgicale [CHU Raymond-Poincaré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Service de réanimation médicale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Medical ICU, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anesthésie-réanimation SAMU94-SMUR94 [Mondor], Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Immunité et Infection, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR113-Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Institut Pascal - Clermont Auvergne (IP), Sigma CLERMONT (Sigma CLERMONT)-Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), CHU Tenon [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Association française contre les myopathies (AFM-Téléthon)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier de Versailles (CHV), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de réanimation medico-chirurgicale, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)
Subjects: Adult, Male, medicine.medical_specialty, Organ Dysfunction Scores, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, 03 medical and health sciences, 0302 clinical medicine, medicine, Systemic capillary leak syndrome, Humans, 030212 general & internal medicine, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, APACHE, Retrospective Studies, business.industry, Immunoglobulins, Intravenous, Retrospective cohort study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, medicine.disease, Respiration, Artificial, 3. Good health, Icu admission, Intensive Care Units, Multicenter study, Shock (circulatory), Fluid Therapy, Female, medicine.symptom, business, Capillary Leak Syndrome
Abstract: Systemic capillary-leak syndrome is a very rare cause of recurrent hypovolemic shock. Few data are available on its clinical manifestations, laboratory findings, and outcomes of those patients requiring ICU admission. This study was undertaken to describe the clinical pictures and ICU management of severe systemic capillary-leak syndrome episodes.This multicenter retrospective analysis concerned patients entered in the European Clarkson's disease (EurêClark) Registry and admitted to ICUs between May 1992 and February 2016.Fifty-nine attacks occurring in 37 patients (male-to-female sex ratio, 1.05; mean ± SD age, 51 ± 11.4 yr) were included. Among 34 patients (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had kappa light chains. ICU-admission hemoglobin and proteinemia were respectively median (interquartile range) 20.2 g/dL (17.9-22 g/dL) and 50 g/L (36.5-58.5 g/L). IV immunoglobulins were infused (IV immunoglobulin) during 15 episodes (25.4%). A compartment syndrome developed during 12 episodes (20.3%). Eleven (18.6%) in-ICU deaths occurred. Bivariable analyses (the 37 patients' last episodes) retained Sequential Organ-Failure Assessment score greater than 10 (odds ratio, 12.9 [95% CI, 1.2-140]; p = 0.04) and cumulated fluid-therapy volume greater than 10.7 L (odds ratio, 16.8 [1.6-180]; p = 0.02) as independent predictors of hospital mortality.We described the largest cohort of severe systemic capillary-leak syndrome flares requiring ICU admission. High-volume fluid therapy was independently associated with poorer outcomes. IV immunoglobulin use was not associated with improved survival; hence, their use should be considered prudently and needs further evaluation in future studies.
Published: 2017
Full Text: View/download PDF

30. Acute Respiratory Failure in Patients with Hematologic Malignancies

Author: Lara Zafrani, Elie Azoulay, Virginie Lemiale, Anne-Sophie Moreau, and Olivier Peyrony
Subjects: Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, High-resolution computed tomography, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Case fatality rate, medicine, Humans, In patient, Acute respiratory failure, 030212 general & internal medicine, Intensive care medicine, Respiratory Distress Syndrome, medicine.diagnostic_test, business.industry, Organ dysfunction, Middle Aged, Intensive care unit, Intensive Care Units, Bronchoalveolar lavage, 030228 respiratory system, Hematologic Neoplasms, Acute Disease, Female, medicine.symptom, business, Respiratory care
Abstract: Acute respiratory failure occurs in up to 50% of patients treated for hematologic malignancies and is associated with a high case fatality rate. Because of residual organ dysfunction and time spent receiving respiratory care, underlying disease control is affected. Early admission to an intensive care unit for acute respiratory failure has proven benefit because it is the best place for rapid implementation of noninvasive diagnostic and therapeutic strategies. This article reviews the clinical approach and diagnostic strategies for acute respiratory failure in patients with hematologic malignancies.
Published: 2017

31. PS1251 CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR BLASTOID MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY

Author: Remy Gressin, Alejandro Martín, P. Fogarty, Alexandra Traverse-Glehen, Danielle Canioni, Anne-Sophie Moreau, M C Béné, Luc Mathieu Fornecker, Barbara Burroni, S. Le Gouill, Olivier Hermine, and M. Baldacini
Subjects: Oncology, medicine.medical_specialty, biology, business.industry, Treatment outcome, Hematology, Blastoid, biology.organism_classification, medicine.disease, Clinical trial, Internal medicine, medicine, Mantle cell lymphoma, business
Published: 2019
Full Text: View/download PDF

32. Infiltrations pulmonaires spécifiques à la phase initiale des leucémies aiguës myéloïdes: le poumon leucémique du diagnostic au traitement

Author: Elie Azoulay, Anne-Sophie Moreau, François Vincent, and Groupe de recherche respiratoire en réanimation oncohématologique
Subjects: Gynecology, medicine.medical_specialty, business.industry, Emergency Medicine, medicine, Emergency Nursing, business
Abstract: Les patients atteints de leucemie aigue myeloide (LAM) peuvent developper une insuffisance respiratoire aigue (IRA) des les premiers jours de la maladie, responsable d’une admission en reanimation dans la moitie des cas. Meme si les infections sont les causes les plus frequentes d’IRA chez ces patients, certains d’entre eux developpent une atteinte pulmonaire specifique de la LAM. On peut en distinguer trois differents types: la leucostase pulmonaire, l’infiltration pulmonaire leucemique et la pneumopathie de lyse. Reconnaitre et differencier ces trois entites est complexe mais possible. Souvent, l’evolution respiratoire permet de trancher a posteriori. Dans cette revue, nous decrivons ces trois differentes entites souvent intriquees et proposons une gestion therapeutique, fondee sur la collaboration entre hematologues et reanimateurs.
Published: 2013
Full Text: View/download PDF

33. Additional file 4: Table S2. of Severe varicella-zoster virus pneumonia: a multicenter cohort study

Author: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Naïke Bigé, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Jean-Damien Ricard, Seguin, Amélie, Souweine, Bertrand, Anne-Sophie Moreau, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, and Canet, Emmanuel
Abstract: Univariate analysis of patient characteristics associated with hospital mortality. (DOC 39 kb)
Published: 2017
Full Text: View/download PDF

34. Additional file 6: Figure S3. of Severe varicella-zoster virus pneumonia: a multicenter cohort study

Author: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Naïke Bigé, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Jean-Damien Ricard, Seguin, Amélie, Souweine, Bertrand, Anne-Sophie Moreau, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, and Canet, Emmanuel
Subjects: body regions, nervous system, viruses, fungi, virus diseases
Abstract: Influence of underlying immunosuppression on mortality in patients with VZV pneumonia. (PDF 1968 kb)
Published: 2017
Full Text: View/download PDF

35. Additional file 4: Table S2. of Severe varicella-zoster virus pneumonia: a multicenter cohort study

Author: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Naïke Bigé, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Jean-Damien Ricard, Seguin, Amélie, Souweine, Bertrand, Anne-Sophie Moreau, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, and Canet, Emmanuel
Abstract: Univariate analysis of patient characteristics associated with hospital mortality. (DOC 39 kb)
Published: 2017
Full Text: View/download PDF

36. Additional file 1: Table S1. of Severe varicella-zoster virus pneumonia: a multicenter cohort study

Author: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Naïke Bigé, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Jean-Damien Ricard, Seguin, Amélie, Souweine, Bertrand, Anne-Sophie Moreau, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, and Canet, Emmanuel
Abstract: Participating centers (n = 29) with the number of cases of VZV pneumonia during the study period (1996–2016). (DOC 45 kb)
Published: 2017
Full Text: View/download PDF

37. Additional file 6: Figure S3. of Severe varicella-zoster virus pneumonia: a multicenter cohort study

Author: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Naïke Bigé, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Jean-Damien Ricard, Seguin, Amélie, Souweine, Bertrand, Anne-Sophie Moreau, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, and Canet, Emmanuel
Subjects: body regions, nervous system, viruses, fungi, virus diseases
Abstract: Influence of underlying immunosuppression on mortality in patients with VZV pneumonia. (PDF 1968 kb)
Published: 2017
Full Text: View/download PDF

38. Additional file 3: Table S3. of Severe varicella-zoster virus pneumonia: a multicenter cohort study

Author: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Naïke Bigé, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Jean-Damien Ricard, Seguin, Amélie, Souweine, Bertrand, Anne-Sophie Moreau, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, and Canet, Emmanuel
Abstract: Mortality evolution during the study period. (DOC 28 kb)
Published: 2017
Full Text: View/download PDF

39. Impact of a Recent Chemotherapy on the Duration and Intensity of the Norepinephrine Support During Septic Shock

Author: Anne-Sophie Moreau, Sébastien Besset, Elie Azoulay, Nicolas Maziers, Danielle Reuter, Virginie Lemiale, Emmanuel Canet, David Schnell, Lara Zafrani, and Etienne Lengliné
Subjects: Male, medicine.medical_specialty, Critical Care, medicine.medical_treatment, Antineoplastic Agents, Critical Care and Intensive Care Medicine, Malignancy, Gastroenterology, Time-to-Treatment, law.invention, Sepsis, Norepinephrine, law, Neoplasms, Internal medicine, medicine, Humans, Vasoconstrictor Agents, Renal replacement therapy, Gram-Positive Bacterial Infections, Aged, Mechanical ventilation, Chemotherapy, Septic shock, business.industry, Cancer, Middle Aged, medicine.disease, Respiration, Artificial, Shock, Septic, Intensive care unit, Anti-Bacterial Agents, Surgery, Renal Replacement Therapy, Emergency Medicine, Female, business
Abstract: The objective of this study was to compare the dose and the duration of vasopressor during septic shock in recently treated cancer patients, untreated cancer patients, and patients without malignancy. This was a retrospective single-center study. This study was performed on a 12-bed medical intensive care unit at a teaching hospital. There were 147 patients admitted to the intensive care unit with septic shock: 82 cancer patients recently treated (TCPs), 20 untreated cancer patients (UCPs), and 45 without malignancy (NPs). The primary outcomes were the maximal dose and the duration of vasopressor support. Treated cancer patients were younger (P < 0.0001) and compared with NPs had less comorbidity (P = 0.003), had more frequently an intra-abdominal source of sepsis (P = 0.011), less frequently a gram-positive bacteria (P = 0.036), and a shorter delay for antibiotics (P = 0.029). All patients received norepinephrine with similar maximal doses (0.66 [0.29-1.5] µg · kg(-1) · min(-1) in TCPs vs. 0.82 [0.41-1.4] µg · kg(-1) · min(-1) in NPs and 0.79 [0.48-1.7] µg · kg(-1) · min(-1) in UCPs; P = 0.61) and duration in the three groups (2 [2-4] days in TCPs vs. 3 [2-4] days in NPs and 3 [2-5] days in UCPs; P = 0.13). Mechanical ventilation (P = 0.11), renal replacement therapy (P = 0.19), and 28-day mortality (43% in TCPs vs. 49% in NPs, and 50% in UCPs; P = 0.77) were similar between the three groups. Cancer patients recently treated with chemotherapy had similar needs in vasopressor support during septic shock compared with untreated cancer patients and patients without malignancy. Mortality was not different in cancer and noncancer patients with septic shock.
Published: 2013
Full Text: View/download PDF

40. Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome

Author: Marc Pineton de Chambrun, Marie Gousseff, Wladimir Mauhin, Jean-Christophe Lega, Marc Lambert, Sophie Rivière, Antoine Dossier, Marc Ruivard, François Lhote, Gilles Blaison, Laurent Alric, Christian Agard, David Saadoun, Julie Graveleau, Martin Soubrier, Marie-Josée Lucchini-Lecomte, Christine Christides, Annick Bosseray, Hervé Levesque, Jean-François Viallard, Nathalie Tieulie, Pierre-Yves Lovey, Sylvie Le Moal, Béatrice Bibes, Giuseppe Malizia, Pierre Abgueguen, François Lifermann, Jacques Ninet, Pierre-Yves Hatron, Zahir Amoura, Arnaud Hot, Laurent Argaud, Romain Hernu, Sylvie de la Salle, Stanislas Ledochowski, Anne-Sophie Moreau, Thomas Papo, Romain Sonneville, Bruno Verdière, Sybille Merceron, Nathalie Zappella, Mickael Landais, Nicolas Limal, Damien Contou, Thomas Similowski, Alexandre Demoule, Bertrand Souweine, Julien Haroche, Julien Boileau, Bernard Lecomte, Thomas Hanslik, Antoine Vieillard-Baron, Nicolas Terzi, Caroline Bulte, Aline Talasczka, Eric Hachulla, Olivier Decaux, Florent Ibouanga, Bertrand Arnulf, Matthieu Groh, Elie Azoulay, Marcel Benedit, Assaad Maalouf, Bruno Moulin, Fleur Cohen-Aubart, Raymond Friolet, Sylvie le Moal, Micheline Pha, Georges-Etienne Rivard, Eric Rondeau, Philippe Debourdeau, Marc Puidupin, François Beloncle, Jérôme Devaquet, Claire Presne, François Liferman, Jean-Marc Mazou, Maude Andrieu, Sylvie Paulus, Yannick Fedun, Jean-Paul Mira, Jean-Herlé Raphalen, Oscar Len Abad, Hervé Devilliers, Alister Rogers, Pascal Godmer, Charles-Edouard Luyt, Alain Combes, Miguel Hie, Alexis Mathian, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP), Centre de recherche en myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS), Department of Internal Medicine, Hôpital pasteur [Colmar], CHU Toulouse [Toulouse], Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Immunologie - Immunopathologie - Immunothérapeutique (I3), Centre hospitalier de Saint-Nazaire, CHU Clermont-Ferrand, Centre hospitalier d'Ajaccio, Centre Hospitalier Henri Duffaut (Avignon), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], Hôpital l'Archet, Centre Hospitalier du Valais Romand [Sion, Switzerland], CHU de Saint-Brieuc, CHP Saint Grégoire, Service des maladies infectieuses et tropicales [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Médecine Interne Dax (MEDECINE INTERNE), Hopital, Service de Médecine Interne, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de médecine interne [Lille], Immunité et Infection, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Analyse Comparée des Pouvoirs (ACP), Université Paris-Est Marne-la-Vallée (UPEM), Université Paris Diderot - Paris 7 (UPD7), Hôpital Bichat - Claude Bernard, Service de soins intensifs, Centre Hospitalier de Versailles André Mignot (CHV), Service de réanimation médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neurophysiologie Respiratoire Expérimentale et Clinique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Department of Clinical Immunology, CHU Strasbourg, Médecine générale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Service de réanimation medico-chirurgicale [CHU Raymond-Poincaré], Service de réanimation médicale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Pontchaillou [Rennes], Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service des maladies infectieuses et tropicales, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Medical ICU, Service de néphrologie, Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), Service d'Hématologie-Oncologie, Hôpital Ste-Justine, Département d'Oncologie (Dep Oncol - AVIGNON), Institut Ste Catherine, Service de Réanimation Médicale et de Médecine Hyperbare [Angers], Service d'anesthésie-réanimation SAMU94-SMUR94 [Mondor], Service de Néphrologie - Médecine Interne, CHU Amiens-Picardie-hôpital Sud, Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne (SOC 1 et SOC 2) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de médecine interne [CHU Bretagnes Atlantique], CHU Bretagnes Atlantique, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), SIGMA Clermont (SIGMA Clermont)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de Medecine Interne, CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS)-Université d'Auvergne - Clermont-Ferrand I (UdA), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), and Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière]
Subjects: Male, medicine.medical_specialty, Paraproteinemias, Context (language use), Intravenous immunoglobulins, Monoclonal gammopathy-associated systemic capillary-leak syndrome, Systemic capillary-leak syndrome, 030204 cardiovascular system & hematology, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Theophylline, Interquartile range, Internal medicine, medicine, Terbutaline, Systemic capillary leak syndrome, Humans, 030212 general & internal medicine, Multiple myeloma, Clarkson disease, business.industry, Hazard ratio, Immunoglobulins, Intravenous, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, General Medicine, Middle Aged, medicine.disease, Survival Analysis, 3. Good health, Surgery, Cohort, Monoclonal, Female, business, Capillary Leak Syndrome, Cohort study
Abstract: International audience; Background: Monoclonal gammopathy-associated systemic capillary-leak syndrome, also known as Clarkson disease, is a rare condition characterized by recurrent life-threatening episodes of capillary hyperpermeability in the context of a monoclonal gammopathy. This study was conducted to better describe the clinical characteristics, natural history, and long-term outcome of monoclonal gammopathy-associated systemic capillary-leak syndrome.Methods: We conducted a cohort analysis of all patients included in the European Clarkson disease (EurêClark) registry between January 1997 and March 2016. From diagnosis to last follow-up, studied outcomes (eg, the frequency and severity of attacks, death, and evolution toward multiple myeloma) and the type of preventive treatments administered were monitored every 6 months.Results: Sixty-nine patients (M/F sex ratio 1:1; mean ± SD age at disease onset 52 ± 12 years) were included in the study. All patients had monoclonal gammopathy of immunoglobulin G type, with kappa light chains in 47 (68%). Median (interquartile range) follow-up duration was 5.1 (2.5-9.7) years. Twenty-four patients (35%) died after 3.3 (0.9-8) years. Fifty-seven (86%) patients received at least one preventive treatment, including intravenous immunoglobulins (IVIg) n = 48 (73.8%), theophylline n = 22 (33.8%), terbutaline n = 22 (33.8%), and thalidomide n = 5 (7.7%). In the 65 patients with follow-up, 5- and 10-year survival rates were 78% (n = 35) and 69% (n = 17), respectively. Multivariate analysis found preventive treatment with IVIg (hazard ratio 0.27; 95% confidence interval, 0.10-0.70; P = .007) and terbutaline (hazard ratio 0.35; 95% confidence interval, 0.13-0.96; P = .041) to be independent predictors of mortality.Conclusions: We describe the largest cohort to date of patients with well-defined monoclonal gammopathy-associated systemic capillary-leak syndrome. Preventive treatment with IVIg was the strongest factor associated with survival, suggesting the use of IVIg as the first line in prevention therapy.
Published: 2016
Full Text: View/download PDF

41. Clinical assessment for identifying causes of acute respiratory failure in cancer patients

Author: Julien Mayaux, Jérôme Lambert, Elie Azoulay, Emmanuel Canet, Anne-Sophie Moreau, Michael Darmon, David Schnell, Antoine Roux, Virginie Lemiale, and Lara Zafrani
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Neutropenia, law.invention, law, Neoplasms, Internal medicine, Pneumonia, Bacterial, medicine, Humans, Hospital Mortality, Intensive care medicine, Aged, Retrospective Studies, business.industry, Bacterial pneumonia, Cancer, Retrospective cohort study, Middle Aged, medicine.disease, Respiration, Artificial, Intensive care unit, Transplantation, Intensive Care Units, Pneumonia, Treatment Outcome, Multivariate Analysis, Female, Crackles, medicine.symptom, Respiratory Insufficiency, business, Algorithms
Abstract: In cancer patients with acute respiratory failure (ARF), early adequate therapy is associated with better outcomes. We investigated the performance of the DIRECT approach, which uses criteria available at the bedside at admission to the intensive care unit (ICU), to identify causes of ARF in cancer patients. This cohort study included cancer patients with ARF of determined aetiology. Associations of aetiological groups with the selected criteria were evaluated using correspondence analysis. 424 cancer patients were included: 201 (47%) with bacterial pneumonia, 131 (31%) with opportunistic infections and 92 (22%) with noninfectious disorders. Mechanical ventilation (both invasive and noninvasive) was needed in 328 (77%) patients, treatment for shock in 217 (51%) patients and dialysis in 82 (19%) patients. 142 (34%) patients died in the ICU. Correspondence plots showed that bacterial pneumonia was associated with neutropenia, solid tumour, multiple myeloma
Published: 2012
Full Text: View/download PDF

42. Hot lungs, bitter cherry: intravascular lymphoma

Author: M. Lecouffe-Desprets, C Bossard, M. Hamidou, Pierre Gallas, A. Enfrein, C. Ansquer, C Agard, Anne Sophie Moreau, V. Génin, and Antoine Néel
Subjects: Pathology, medicine.medical_specialty, Fever, Genes, myc, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, medicine, Humans, Skin pathology, Skin, Positron Emission Tomography-Computed Tomography, Lung, business.industry, General Medicine, Middle Aged, Intravascular lymphoma, medicine.disease, Genes, bcl-2, Lymphoma, Dyspnea, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Lymphoma, Large B-Cell, Diffuse, business
Published: 2017
Full Text: View/download PDF

43. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL

Author: Jehan Dupuis, Selim Corm, Remy Gressin, Roch Houot, Christiane Mounier, Sylvain Carras, Caroline Dartigeas, M. Macro, Ghandi Damaj, Nicolas Daguindau, Mary Callanan, Jean-Michel Pignon, Anne-Sophie Moreau, S. Le Gouill, Adrien Tempescul, P. Feugier, Fabrice Jardin, Guillaume Cartron, Luc Mathieu Fornecker, I. Ysebaert, A. Bannos, Lionel Karlin, J. Fleury, Anna Schmitt, and Cecile Chabrot
Subjects: Cancer Research, Pediatrics, medicine.medical_specialty, Group trial, business.industry, Hematology, General Medicine, First line treatment, 03 medical and health sciences, Regimen, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Molecular Response, Internal medicine, medicine, business, 030215 immunology
Published: 2017
Full Text: View/download PDF

44. Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis

Author: Amélie Seguin, Anne-Sophie Moreau, Virginie Lemiale, Gastón Burghi, Elie Azoulay, Eric Mariotte, Benoit Schlemmer, Claire Lacroix, Emmanuel Canet, Jérôme Lambert, Patricia Ribaud, and David Schnell
Subjects: Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Neutropenia, Critical Care and Intensive Care Medicine, Aspergillosis, Intensive care, Internal medicine, medicine, Humans, Retrospective Studies, Invasive Pulmonary Aspergillosis, Mechanical ventilation, Voriconazole, Hematology, business.industry, Mortality rate, Middle Aged, medicine.disease, Respiration, Artificial, Treatment Outcome, Hematologic Neoplasms, Anesthesia, Concomitant, Female, business, medicine.drug
Abstract: Invasive pulmonary aspergillosis (IPA) is a life-threatening infection documented in up to 15% of hematology patients who require intensive care for acute respiratory failure. We report outcomes in hematology patients given mechanical ventilation (MV) with IPA. Retrospective study of all hematology patients given MV with IPA between January 1998 and March 2011 at a single center. Predictors of 6-month survival or mortality were identified using multivariable analysis. We studied 67 patients including 49 (73%) with neutropenia, 23 (34%) with long-term steroid therapy, and 14 (21%) with allogeneic bone marrow transplantation. Incidence of IPA in the ICU decreased between 1998 and 2011, and mortality in patients receiving mechanical ventilation did not change. IPA was confirmed in 6 patients by autopsy and was probable in 61 patients based on host factors, clinical and radiographic features, and either Aspergillus isolation (50 patients) or Aspergillus antigen detection alone (11 patients). Concomitant bacterial infections were documented in 24 (36%) patients. ICU and 6-month mortality rates were 67 and 82%, respectively. Mortality was stable throughout the study period. Concomitant bacterial infection was independently associated with higher mortality [HR, 2.1 (1.2–3.8)]. Mortality was lower in patients given voriconazole [OR, 0.5 (0.3–0.9)]. Hospital mortality remains high in hematology patients requiring MV with IPA, particularly when concommittant infection occurred. The use of voriconazole improved survival.
Published: 2011
Full Text: View/download PDF

45. Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death

Author: Anne-Sophie Moreau, V. Dubruille, S. Le Gouill, Thomas Gastinne, P. Arnaud, A. Lok, P. Moreau, A. Tabah, Christophe Leux, N. Blin, Béatrice Mahé, Clara Sortais, and S. Howlett
Subjects: Oncology, medicine.medical_specialty, business.industry, Follicular lymphoma, Hematology, Disease, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Risk of death, business, 030215 immunology
Published: 2018
Full Text: View/download PDF

46. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

Author: Renee Wright, Judith Runnels, Antonio Sacco, Barrett J. Rollins, Abdel Kareem Azab, Nicholas Burwick, Teru Hideshima, Costas Pitsillides, Xavier Leleu, Alicia L. Carlson, Feda Azab, Beatriz Ospina, Molly R. Melhem, Nikhil C. Munshi, Mena Farag, Irene M. Ghobrial, Charles P. Lin, Andrew L. Kung, Xiaoying Jia, Clemens Alt, Aldo M. Roccaro, Anne-Sophie Moreau, Hai T. Ngo, and Kenneth C. Anderson
Subjects: Stromal cell, Cells, Immunology, Apoptosis, Biology, Medical and Health Sciences, Biochemistry, Mice, Multiple myeloma, medicine, Bone marrow, Lymphoid Neoplasia, Bortezomib, Plerixafor, Cell Biology, Hematology, Transfection, medicine.disease, Haematopoiesis, medicine.anatomical_structure, Animal experimentation, Cancer research, Clinical Medicine, Stem cell, medicine.drug
Abstract: The interaction of multiple myeloma (MM) cells with their microenvironment in the bone marrow (BM) provides a protective environment and resistance to therapeutic agents. We hypothesized that disruption of the interaction of MM cells with their BM milieu would lead to their sensitization to therapeutic agents such as bortezomib, melphalan, doxorubicin, and dexamethasone. We report that the CXCR4 inhibitor AMD3100 induces disruption of the interaction of MM cells with the BM reflected by mobilization of MM cells into the circulation in vivo, with kinetics that differed from that of hematopoietic stem cells. AMD3100 enhanced sensitivity of MM cell to multiple therapeutic agents in vitro by disrupting adhesion of MM cells to bone marrow stromal cells (BMSCs). Moreover, AMD3100 increased mobilization of MM cells to the circulation in vivo, increased the ratio of apoptotic circulating MM cells, and enhanced the tumor reduction induced by bortezomib. Mechanistically, AMD3100 significantly inhibited Akt phosphorylation and enhanced poly(ADP-ribose) polymerase (PARP) cleavage as a result of bortezomib, in the presence of BMSCs in coculture. These experiments provide a proof of concept for the use of agents that disrupt interaction with the microenvironment for enhancement of efficacy of cytotoxic agents in cancer therapy.
Published: 2009
Full Text: View/download PDF

47. Métastase osseuse simulant une artérite temporale : à propos de deux observations

Author: Pascal Chevalet, Anne Sophie Moreau, Christian Agard, M. Hamidou, and Antoine Néel
Subjects: Gynecology, medicine.medical_specialty, business.industry, Diagnostico diferencial, Gastroenterology, Internal Medicine, medicine, business, Vasculitis, medicine.disease
Abstract: Resume Introduction La maladie de Horton (MH) est une vascularite du sujet âge dont le diagnostic formel repose sur la biopsie de l’artere temporale. Cependant, celle-ci est negative dans 30 % des cas, le diagnostic repose alors sur la clinique et l’exclusion des diagnostics differentiels. A l’inverse, les faux positifs histologiques sont exceptionnels. Observations Nous rapportons les observations de deux patientes ayant presente un tableau evocateur de la MH, associant des cephalees hemicrâniennes subaigues avec hyperesthesie du cuir chevelu et un syndrome inflammatoire, revelant une metastase de la voute crânienne. Chez une patiente, la biopsie de l’artere temporale (BAT) retrouvait un infiltrat inflammatoire de la paroi arterielle. Conclusion Ces observations montrent qu’une atteinte de la voute crânienne peut simuler une MH et illustrent les limites de la clinique dans le diagnostic de cette affection.
Published: 2009
Full Text: View/download PDF

48. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

Author: Christopher J. Patterson, Steven P. Treon, Xavier Leleu, Irene M. Ghobrial, Evdoxia Hatjiharissi, Jacob D. Soumerai, Vinod Bakthavachalam, Zachary R. Hunter, Allen W. Ho, Sigitas Verselis, Edward A. Fox, Ruben D. Carrasco, Aldo M. Roccaro, Robert Manning, Anne-Sophie Moreau, Susanna Hamilton, Sophia Adamia, Daniel Ditzel Santos, and Lian Xu
Subjects: Adult, Male, XBP1, Cellular differentiation, Plasma Cells, Gene Expression, Biology, Statistics, Nonparametric, Genes, Regulator, PRDM1, Gene expression, medicine, Humans, Gene, Aged, Regulator gene, Aged, 80 and over, B-Lymphocytes, Reverse Transcriptase Polymerase Chain Reaction, Electrophoresis, Capillary, Waldenstrom macroglobulinemia, Cell Differentiation, Sequence Analysis, DNA, Hematology, Middle Aged, medicine.disease, Reverse transcription polymerase chain reaction, Case-Control Studies, Cancer research, Female, Waldenstrom Macroglobulinemia
Abstract: Waldenstrom Macroglobulinemia (WM) is a B-cell malignancy characterized by excess bone marrow (BM) lymphoplasmacytic cells (LPC). The accumulation of LPC in WM may represent a failure of B-cells to properly differentiate into plasma cells. The present study investigated transcriptional expression of genes involved in late B-cell differentiation, including PRDM1, PAX5, XBP1 transcripts and ERN1, in BM B-cells from 31 patients with WM and six healthy donors. Real time reverse transcription polymerase chain reaction (RT-PCR) determined that approximately 80% of the patients had high XBP1 spliced mRNA expression, 80% of whom had high mRNA ERN1alpha expression. XBP1, PRDM1 and PAX5 mRNA was present in all patients studied. Using relative quantitative RT-PCR we isolated two groups with low and high expression of XBP1, XBP1 spliced and ERN1alpha. Sequence analysis showed germline polymorphisms in all genes studied. These data depict for the first time a heterogeneous expression pattern of the genes involved in late differentiation process of plasma cells in patients with WM and propose a role of XBP1-ERN1alpha in WM pathogenesis.
Published: 2009
Full Text: View/download PDF

49. The HMG-CoA inhibitor, simvastatin, triggersin vitroanti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

Author: Aldo M. Roccaro, Christopher J. Patterson, Bryan Ciccarelli, Irene M. Ghobrial, Xiaoying Jia, Xavier Leleu, Hai T. Ngo, Steven P. Treon, Jacob D. Soumerai, Zachary R. Hunter, Robert Manning, Kelly O’Connor, Anne-Sophie Moreau, Lian Xu, Evdoxia Hatjiharissi, and Antonio Sacco
Subjects: MAPK/ERK pathway, Simvastatin, medicine.medical_specialty, Apoptosis, In Vitro Techniques, Biology, CD19, Internal medicine, medicine, Humans, Extracellular Signal-Regulated MAP Kinases, Protein kinase A, Protein kinase B, Kinase, Cell growth, Hematology, Endocrinology, Immunoglobulin M, HMG-CoA reductase, biology.protein, Cancer research, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Waldenstrom Macroglobulinemia, Proto-Oncogene Proteins c-akt, medicine.drug
Abstract: Summary Waldenstrom macroglobulinaemia (WM) is an incurable lymphoplasmacytic lymphoma with secretion of serum monoclonal immunoglobulin M (IgM). We previously showed that patients receiving cholesterol-lowering statins, had the lowest IgM value in a large cohort of patients with WM. Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor, induced inhibition of proliferation, cytotoxic effect and apoptosis in IgM secreting cell lines as well as in primary CD19 + WM cells. Interestingly, those effects were reversed by addition of mevalonate and geranylgeranylpyrophosphate, demonstrating that simvastatin inhibited cell growth, survival and IgM secretion on BCWM.1 WM cells by inhibition of geranylgeranylated proteins. Furthermore, simvastatin overcame tumour cell growth induced by co-culture of WM cells with bone-marrow stromal cells. Simvastatin also decreased IgM secretion by BCWM.1 cells at an early time-point that had not affected cell survival. Simvastatin-induced cytotoxicity was preceded by a decrease in Akt (protein kinase B, PKB) and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathways at 18 h. In addition, simvastatin induced an increase in stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/ JNK) MAPK followed by caspase-8, -9, -3 and poly(ADP-ribose) polymerase (PARP) cleavages at 18 h, leading to apoptosis. Furthermore, simvastatin enhanced the cytotoxicity induced by bortezomib, fludarabine and dexamethasone. Our studies therefore support our earlier observation of statin-mediated anti-WM activity and provide the framework for future clinical trials testing simvastatin in WM.
Published: 2008
Full Text: View/download PDF

50. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia

Author: Irene M. Ghobrial, Nicholas Burwick, Xiaoying Jia, Judith Runnels, Antonio Sacco, Hai T. Ngo, Aldo M. Roccaro, Molly R. Melhem, Jack Y. Lee, Anne-Sophie Moreau, Abdel Kareem Azab, Mena Farag, Xavier Leleu, Feda Azab, and Robert Sackstein
Subjects: Benzylamines, Receptors, CXCR4, Chemokine, Stromal cell, MAP Kinase Signaling System, Immunology, Integrin alpha4beta1, Cyclams, Biochemistry, Cell Line, Phosphatidylinositol 3-Kinases, Cell Movement, Heterocyclic Compounds, Cell Adhesion, medicine, Humans, Stromal cell-derived factor 1, RNA, Small Interfering, Cell adhesion, Base Sequence, Neoplasia, biology, Cell adhesion molecule, Endothelial Cells, Cell migration, Cell Biology, Hematology, Chemokine CXCL12, Fibronectins, Cell biology, medicine.anatomical_structure, biology.protein, RNA Interference, Receptors, Chemokine, Bone marrow, Stromal Cells, Waldenstrom Macroglobulinemia, Signal Transduction, Homing (hematopoietic)
Abstract: Waldenstrom macroglobulinemia (WM) is characterized by widespread involvement of the bone marrow at the time of diagnosis, implying continuous homing of WM cells into the marrow. The mechanisms by which trafficking of the malignant cells into the bone marrow has not been previously elucidated. In this study, we show that WM cells express high levels of chemokine and adhesion receptors, including CXCR4 and VLA-4. We showed that CXCR4 was essential for the migration and trans-endothelial migration of WM cells under static and dynamic shear flow conditions, with significant inhibition of migration using CXCR4 knockdown or the CXCR4 inhibitor AMD3100. Similarly, CXCR4 or VLA-4 inhibition led to significant inhibition of adhesion to fibronectin, stromal cells, and endothelial cells. Decreased adhesion of WM cells to stromal cells by AMD3100 led to increased sensitivity of these cells to cytotoxicity by bortezomib. To further investigate the mechanisms of CXCR4-dependent adhesion, we showed that CXCR4 and VLA-4 directly interact in response to SDF-1, we further investigated downstream signaling pathways regulating migration and adhesion in WM. Together, these studies demonstrate that the CXCR4/SDF-1 axis interacts with VLA-4 in regulating migration and adhesion of WM cells in the bone marrow microenvironment.
Published: 2008
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Journal

Database

Publisher

144 results on '"Anne- Sophie Moreau"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources